The decision expands the drug’s indication to include first- and second-line use in children.
SALT LAKE CITY – Non-ionizing imaging technique could reveal early lung ventilation deficits in children undergoing hematopoietic stem cell...
SAN DIEGO – Bleeding episodes and need for treatment were more frequent among boys with types 1 and 2 von Willebrand disease.
The U.S. hemophilia drug market, which serves about 20,000 patients, is worth $4.6 billion a year.
“There aren’t a lot of options available to Medicaid programs in terms of controlling costs, because we don’t set the initial costs”
From the Journals
Identify barriers to prophylactic antibiotics for sickle cell patients at the time of health care interventions.
Eltrombopag, from Novartis, will get expedited review for first-line treatment of severe aplastic anemia. It is already approved as a second-line...
This is the first FDA approval for hydroxyurea in pediatric patients with sickle cell anemia.
CONCORD, N.C. – Transitional programs could help teenage patients continue self-care and avoid risk behaviors.
ATLANTA – Emicizumab safely prevents or substantially reduces bleeds in children with hemophilia A with inhibitors.